Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 6/2016

01-12-2016 | Research Article

[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

Authors: Richard Laforest, Suzanne E. Lapi, Reiko Oyama, Ron Bose, Adel Tabchy, Bernadette V. Marquez-Nostra, Jennifer Burkemper, Brian D. Wright, Jennifer Frye, Sarah Frye, Barry A. Siegel, Farrokh Dehdashti

Published in: Molecular Imaging and Biology | Issue 6/2016

Login to get access

Abstract

Purpose

The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer.

Procedures

Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model.

Results

High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered.

Conclusion

[89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.
Appendix
Available only for authorised users
Literature
1.
2.
Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRefPubMed
3.
Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423CrossRefPubMedPubMedCentral
4.
Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 353:1673–1684CrossRefPubMed
5.
Nahta R, Yu D, Hung MC et al (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–280CrossRefPubMed
6.
Burris HA III, Rugo HS, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405CrossRefPubMed
7.
Mack L, Kerkvliet N, Doig G et al (1997) Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. Hum Pathol 28:974–979CrossRefPubMed
8.
Rosenthal SI, Depowski PL, Sheehan CE et al (2002) Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Applied immunohistochemistry & molecular morphology. Appl Immunohistochem Mol Morph 10:40–46CrossRef
9.
Barron JJ, Cziraky MJ, Weisman T et al (2009) HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist 14:760–768PubMed
10.
Pedrini JL, Francalacci Savaris R, Casales Schorr M et al (2011) The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer. Tumori 97:704–710PubMed
11.
Solomayer EF, Becker S, Pergola-Becker G et al (2006) Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Canc Res Treat 98:179–184CrossRef
12.
Wulfing P, Borchard J, Buerger H et al (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12:1715–1720CrossRefPubMed
13.
Dijkers EC, de Vries EG, Kosterink JG et al (2008) Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy. Curr Pharmacol Des 14:3348–3362CrossRef
14.
Lower EE, Glass E, Blau R et al (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301–306CrossRefPubMed
15.
16.
Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK et al (2003) Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 127:1451–1457PubMed
17.
Capala J, Bouchelouche K (2010) Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy. Curr Opin Oncol 22:559–566CrossRefPubMedPubMedCentral
18.
Dijkers EC, Oude Munnink TH, Kosterink JG et al (2010) Biodistribution of [89Zr]-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Therap 87:586–592CrossRef
19.
Kurihara H, Hamada A, Yoshida M et al (2015) [64Cu]-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. Eur J Nucl Med Mol Imaging Res 5:8
20.
Mortimer JE, Bading JR, Colcher DM et al (2014) Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using [64Cu]-DOTA-trastuzumab PET. J Nucl Med 55:23–29CrossRefPubMed
21.
Gaykema SB, Schroder CP, Vitfell-Rasmussen J et al (2014) [89Zr]-trastuzumab and [89Zr]-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res 20:3945–3954CrossRefPubMed
22.
Beylergil V, Morris PG, Smith-Jones PM et al (2013) Pilot study of [68Ga]-DOTA-F(ab′)2-trastuzumab in patients with breast cancer. Nucl Med Commun 34:1157–1165PubMedPubMedCentral
23.
Baum RP, Prasad V, Muller D et al (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 51:892–897CrossRefPubMed
24.
Gebhart G, Lamberts LE, Wimana Z et al (2015) Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. Ann Oncol. doi:10.​1093/​annonc/​mdv577 PubMed
25.
Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013CrossRefPubMed
26.
Vosjan MJ, Perk LR, Visser GW et al (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 5:739–743CrossRefPubMed
27.
Wooten AL, Madrid E, Schweitzer GD et al (2013) Routine production of Zr-89 using an automated module. Appl Sci 3:593–613CrossRef
28.
29.
Lindmo T, Boven E, Cuttitta F et al (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77–89CrossRefPubMed
30.
Lemmens HJ, Bernstein DP, Brodsky JB (2006) Estimating blood volume in obese and morbidly obese patients. Obes Surg 16:773–776CrossRefPubMed
31.
Vance GH, Barry TS, Bloom KJ et al (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133:611–612PubMed
32.
Lewis JT, Ketterling RP, Halling KC et al (2005) Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 124:273–281CrossRefPubMed
33.
Brunelli M, Manfrin E, Martignoni G et al (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131:678–682CrossRefPubMed
34.
Boyer AP, Collier TS, Vidavsky I et al (2013) Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. Mol Cell Prot 12:180–193CrossRef
35.
36.
Price-Schiavi SA, Jepson S, Li P et al (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Intl J Cancer 99:783–791CrossRef
37.
Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402CrossRefPubMed
38.
Zhang S, Huang WC, Li P et al (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Med 17:461–469CrossRefPubMed
Metadata
Title
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Authors
Richard Laforest
Suzanne E. Lapi
Reiko Oyama
Ron Bose
Adel Tabchy
Bernadette V. Marquez-Nostra
Jennifer Burkemper
Brian D. Wright
Jennifer Frye
Sarah Frye
Barry A. Siegel
Farrokh Dehdashti
Publication date
01-12-2016
Publisher
Springer US
Published in
Molecular Imaging and Biology / Issue 6/2016
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-016-0951-z

Other articles of this Issue 6/2016

Molecular Imaging and Biology 6/2016 Go to the issue

Research Article

pH-Sensitive, Long-Circulating Liposomes as an Alternative Tool to Deliver Doxorubicin into Tumors: a Feasibility Animal Study

Research Article

Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography

Research Article

Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging

Research Article

Synthesis and In Vivo Imaging of N-(3-[11C]Methoxybenzyl)-2-(3-Methoxyphenyl)ethylaniline as a Potential Targeting Agent for P-glycoprotein

Research Article

Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas

Research Article

L p Regularization for Bioluminescence Tomography Based on the Split Bregman Method